Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 2
2020 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.
Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, Bézay N, Klingler A, Lingnau K, Schneider M, Lundberg U, Meinke A, Larcher-Senn J, Čorbic-Ramljak I, Eder-Lingelbach S, Dubischar K, Bender W. Wressnigg N, et al. Among authors: eder lingelbach s. Lancet Infect Dis. 2020 Oct;20(10):1193-1203. doi: 10.1016/S1473-3099(20)30238-3. Epub 2020 Jun 1. Lancet Infect Dis. 2020. PMID: 32497524 Clinical Trial.
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.
Adlbrecht C, Wurm R, Depuydt P, Spapen H, Lorente JA, Staudinger T, Creteur J, Zauner C, Meier-Hellmann A, Eller P, Laenen MV, Molnár Z, Várkonyi I, Schaaf B, Héjja M, Šrámek V, Schneider H, Kanesa-Thasan N, Eder-Lingelbach S, Klingler A, Dubischar K, Wressnigg N, Rello J. Adlbrecht C, et al. Among authors: eder lingelbach s. Crit Care. 2020 Mar 4;24(1):74. doi: 10.1186/s13054-020-2792-z. Crit Care. 2020. PMID: 32131866 Free PMC article. Clinical Trial.
Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.
Taucher C, Barnett ED, Cramer JP, Eder-Lingelbach S, Jelinek T, Kadlecek V, Kiermayr S, Mills DJ, Pandis D, Reiner D, Dubischar KL. Taucher C, et al. Among authors: eder lingelbach s. Travel Med Infect Dis. 2020 Mar-Apr;34:101616. doi: 10.1016/j.tmaid.2020.101616. Epub 2020 Mar 7. Travel Med Infect Dis. 2020. PMID: 32156630 Free article. Clinical Trial.
Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.
Kadlecek V, Borja-Tabora CF, Eder-Lingelbach S, Gatchalian S, Kiermayr S, Sablan B Jr, Kundi M, Taucher C, Dubischar KL. Kadlecek V, et al. Among authors: eder lingelbach s. Pediatr Infect Dis J. 2018 Sep;37(9):e233-e240. doi: 10.1097/INF.0000000000002124. Pediatr Infect Dis J. 2018. PMID: 29912844 Clinical Trial.
Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
Dubischar KL, Kadlecek V, Sablan JB, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Kiermayr S, Spruth M, Westritschnig K. Dubischar KL, et al. Among authors: eder lingelbach s. Pediatr Infect Dis J. 2017 Sep;36(9):898-904. doi: 10.1097/INF.0000000000001615. Pediatr Infect Dis J. 2017. PMID: 28430748 Clinical Trial.
Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.
Jelinek T, Cromer MA, Cramer JP, Mills DJ, Lessans K, Gherardin AW, Barnett ED, Hagmann SHF, Askling HH, Kiermayr S, Kadlecek V, Eder-Lingelbach S, Taucher C, Dubischar KL. Jelinek T, et al. Among authors: eder lingelbach s. Travel Med Infect Dis. 2018 Mar-Apr;22:18-24. doi: 10.1016/j.tmaid.2018.03.003. Epub 2018 Mar 13. Travel Med Infect Dis. 2018. PMID: 29549036 Free article. Clinical Trial.